Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Lawrence Charles Paoletti, Ph.D.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women
Division of Infectious Diseases, MCP 570
181 Longwood Ave
Boston MA 02115
Phone617/525-7878
Fax617/731-1541

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Arjunaraja S, Paoletti LC, Snapper CM. Structurally identical capsular polysaccharide expressed by intact group B streptococcus versus Streptococcus pneumoniae elicits distinct murine polysaccharide-specific IgG responses in vivo. J Immunol. 2012 Jun 1; 188(11):5238-46.
    View in: PubMed
  2. Jiang S, Park SE, Yadav P, Paoletti LC, Wessels MR. Regulation and function of pilus island 1 in group B streptococcus. J Bacteriol. 2012 May; 194(10):2479-90.
    View in: PubMed
  3. Guttormsen HK, Mascuch SJ, West JC, Paoletti LC. A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus. Hum Vaccin. 2009 Jul; 5(7):461-6.
    View in: PubMed
  4. Paoletti LC, Guttormsen HK, Christian MS, Hoberman AM, McInnes P. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Hum Vaccin. 2008 Nov-Dec; 4(6):435-43.
    View in: PubMed
  5. Guttormsen HK, Liu Y, Paoletti LC. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum Vaccin. 2008 Sep-Oct; 4(5):370-4.
    View in: PubMed
  6. Coyne MJ, Chatzidaki-Livanis M, Paoletti LC, Comstock LE. Role of glycan synthesis in colonization of the mammalian gut by the bacterial symbiont Bacteroides fragilis. Proc Natl Acad Sci U S A. 2008 Sep 2; 105(35):13099-104.
    View in: PubMed
  7. Yang HH, Mascuch SJ, Madoff LC, Paoletti LC. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein. Clin Vaccine Immunol. 2008 Jul; 15(7):1035-41.
    View in: PubMed
  8. Guttormsen HK, Paoletti LC, Mansfield KG, Jachymek W, Jennings HJ, Kasper DL. Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5903-8.
    View in: PubMed
  9. Guttormsen H-K, Paoletti LC, Mansfield KG, Jachymek W, Jennings HJ and DL Kasper. . Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM to IgG switching. Proc. Nat. Acad. Sci. USA. 2008; (105):5903-5908.
  10. Yang H-H, Mascuch S, Madoff LC and LC Paoletti. Recombinant group B streptococcal alpha-like protein 3 is an effective immunogen and carrier protein. Clin. Vacc. Immunol. 2008; (15):1035-1041.
  11. Coyne MJ, Chatzidaki-Livanis M, Paoletti LC and LE Comstock. Role of glycan synthesis in colonization of the mammalian gut by the bacterial symbiont Bacteroides fragilis. Proc. Nat. Acad. Sci. USA. 2008; (105):13098-13103.
  12. Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun. 2007 Jul; 75(7):3455-61.
    View in: PubMed
  13. Johri AK, Margarit I, Broenstrup M, Brettoni C, Hua L, Gygi SP, Telford JL, Grandi G, Paoletti LC. Transcriptional and proteomic profiles of group B Streptococcus type V reveal potential adherence proteins associated with high-level invasion. Infect Immun. 2007 Mar; 75(3):1473-83.
    View in: PubMed
  14. Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, Grandi G, Rappuoli R. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol. 2006 Dec; 4(12):932-42.
    View in: PubMed
  15. Baker CJ, Rench MA, Paoletti LC, Edwards MS. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 2007 Jan 2; 25(1):55-63.
    View in: PubMed
  16. Ramaswamy SV, Ferrieri P, Flores AE, Paoletti LC. Molecular characterization of nontypeable group B streptococcus. J Clin Microbiol. 2006 Jul; 44(7):2398-403.
    View in: PubMed
  17. Ramaswamy SV, Ferrieri P, Madoff LC, Flores AE, Kumar N, Tettelin H, Paoletti LC. Identification of novel cps locus polymorphisms in nontypable group B Streptococcus. J Med Microbiol. 2006 Jun; 55(Pt 6):775-83.
    View in: PubMed
  18. Travaglione S, Bruni BM, Falzano L, Filippini P, Fabbri A, Paoletti L, Fiorentini C. Multinucleation and pro-inflammatory cytokine release promoted by fibrous fluoro-edenite in lung epithelial A549 cells. Toxicol In Vitro. 2006 Sep; 20(6):841-50.
    View in: PubMed
  19. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, Tettelin H, Brettoni C, Iacobini ET, Rosini R, D'Agostino N, Miorin L, Buccato S, Mariani M, Galli G, Nogarotto R, Nardi Dei V, Vegni F, Fraser C, Mancuso G, Teti G, Madoff LC, Paoletti LC, Rappuoli R, Kasper DL, Telford JL, Grandi G. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005 Jul 1; 309(5731):148-50.
    View in: PubMed
  20. Sinha A, Lieu TA, Paoletti LC, Weinstein MC, Platt R. The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. Vaccine. 2005 May 2; 23(24):3187-95.
    View in: PubMed
  21. Johri AK, Patwardhan V, Paoletti LC. Growth rate and oxygen regulate the interactions of group B Streptococcus with polarized respiratory epithelial cells. Can J Microbiol. 2005 Apr; 51(4):283-6.
    View in: PubMed
  22. Mikamo H, Johri AK, Paoletti LC, Madoff LC, Onderdonk AB. Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci. Infect Immun. 2004 Aug; 72(8):4716-22.
    View in: PubMed
  23. Ferrieri P, Hillier SL, Krohn MA, Moore D, Paoletti LC, Flores AE. Characterization of vaginal & rectal colonization with multiple serotypes of group B streptococci using multiple colony picks. Indian J Med Res. 2004 May; 119 Suppl:208-12.
    View in: PubMed
  24. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004 Mar 15; 189(6):1103-12.
    View in: PubMed
  25. Johri AK, Patwardhan V, Paoletti LC. Growth rate and oxygen level influence the interactions of group B Streptococcus with polarized respiratory epithelial cells. 104th General ASM Meeting, New Orleans, LA. 2004; (Session 270, Abstract 4925).
  26. Johri AK, Padilla J, Malin G, Paoletti LC. Oxygen regulates invasiveness and virulence of group B streptococcus. Infect Immun. 2003 Dec; 71(12):6707-11.
    View in: PubMed
  27. Paoletti LC, Kasper DL. Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther. 2003 Sep; 3(6):975-84.
    View in: PubMed
  28. Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003 Jul 1; 188(1):66-73.
    View in: PubMed
  29. Johri AK, Padilla J, Malin G, Paoletti LC. Oxygen regulates invasiveness of group B Streptococcus. 103rd General ASM Meeting, Washington, DC. 2003; (Session 27, Abstract 2269).
  30. Palazzi DL, Rench MA, Paoletti LC, Kasper DL, Baker CJ. Group B streptococcal (GBS) type V capsular polysaccharide (CPS)-tetanus toxoid (V-TT) conjugate vaccine (CV) in healthy adults 65 to 85 years of age. Infect. Dis. Soc. of America. 2003.
  31. Paoletti LC. Academic pursuits of vaccines against group B Streptococcus. R.W. Ellis and B.R. Brodeur (eds.) New Bacterial Vaccines. Eurekah.com and Kluwer Academic/Plenum. 2003; 174-191.
  32. dwards MS, LC Paoletti, CJ Baker. Vaccines against group B Streptococcus. MM Levine, JB Kaper, R Rappuoli, M. Liu, M.F. Good (eds.) New Generation Vaccines Marcel-Dekker. 2003; 711-721.
  33. Paoletti LC, Kennedy RC. Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3. J Infect Dis. 2002 Dec 1; 186(11):1597-602.
    View in: PubMed
  34. Paoletti LC, Madoff LC. Vaccines to prevent neonatal GBS infection. Semin Neonatol. 2002 Aug; 7(4):315-23.
    View in: PubMed
  35. Paoletti LC, Kasper DL. Conjugate vaccines against group B Streptococcus types IV and VII. J Infect Dis. 2002 Jul 1; 186(1):123-6.
    View in: PubMed
  36. Guttormsen HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper DL. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun. 2002 Apr; 70(4):1724-38.
    View in: PubMed
  37. Ferrieri P, Hillier SL, Krohn MA, Moore D, Paoletti LC, Flores AE. Characterization of vaginal and rectal colonization with multiple serotypes of group B streptococci using multiple colony picks. XVth LISSSD. Goa, India. 2002.
  38. Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine. 2001 Nov 12; 20(3-4):370-6.
    View in: PubMed
  39. Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun. 2001 Nov; 69(11):6696-701.
    View in: PubMed
  40. Malin G, Paoletti LC. Use of a dynamic in vitro attachment and invasion system (DIVAS) to determine influence of growth rate on invasion of respiratory epithelial cells by group B Streptococcus. Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13335-40.
    View in: PubMed
  41. Paoletti LC, inventor. Improved conjugate vaccines. 2001.
  42. Paoletti LC. Potency of clinical group B streptococcal conjugate vaccines. Vaccine. 2001 Feb 28; 19(15-16):2118-26.
    View in: PubMed
  43. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, Kasper DL. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000 Oct; 182(4):1129-38.
    View in: PubMed
  44. Paoletti LC, Pinel J, Kennedy RC, Kasper DL. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J Infect Dis. 2000 Feb; 181(2):653-8.
    View in: PubMed
  45. Paoletti LC, Baker CJ, Kasper DL. Group B streptococcal conjugate vaccines. 9th International Congress of Infectious Diseases. Buenos Aires, Argentina. 2000.
  46. Paoletti LC, Madoff LC, Kasper DL. Surface structures of group B Streptococcus important in human immunity. V.A. Fischetti, R. Novick, J. Ferretti, D. Portnoy, and J. Rood (eds.). Gram positive pathogens. American Society for Microbiology. 2000; 137-153.
  47. Paoletti LJ, Bradford J, Paoletti LC. A serotype VIII strain among colonizing group B streptococcal isolates in Boston, Massachusetts. J Clin Microbiol. 1999 Nov; 37(11):3759-60.
    View in: PubMed
  48. Davies JK, Paoletti LC, McDuffie RS, Madoff LC, Lee S, Eskens J, Gibbs RS. A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection. Am J Obstet Gynecol. 1999 Oct; 181(4):803-8.
    View in: PubMed
  49. Ross RA, Madoff LC, Paoletti LC. Regulation of cell component production by growth rate in the group B Streptococcus. J Bacteriol. 1999 Sep; 181(17):5389-94.
    View in: PubMed
  50. Paoletti LC, Pinel J, Johnson KD, Reinap B, Ross RA, Kasper DL. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. J Infect Dis. 1999 Sep; 180(3):892-5.
    View in: PubMed
  51. Kasper DL, Wessels MR, Guttormsen HK, Paoletti LC, Edwards MS, Baker CJ. Measurement of human antibodies to type III group B Streptococcus. Infect Immun. 1999 Aug; 67(8):4303-5.
    View in: PubMed
  52. Gravekamp C, Kasper DL, Paoletti LC, Madoff LC. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun. 1999 May; 67(5):2491-6.
    View in: PubMed
  53. Lachenauer CS, Kasper DL, Shimada J, Ichiman Y, Ohtsuka H, Kaku M, Paoletti LC, Ferrieri P, Madoff LC. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis. 1999 Apr; 179(4):1030-3.
    View in: PubMed
  54. Paoletti LC, Madoff LC. Vaccines for the prevention of group B streptococcal disease. UpToDate in Medicine. 1999; 7(3).
  55. Paoletti LC. Considerations in the production of vaccines for use in phase 1 clinical trials and preparation of the manufacturer’s protocol. L.C. Paoletti and P.M.McInnes (eds.). Vaccines: from concept to clinic. A guide to the development and clinical testing of vaccines for human use. 1999; 77-87.
  56. Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1999 Jan; 179(1):142-50.
    View in: PubMed
  57. Paoletti LC, McInnes PM. . Vaccines: from concept to clinic. A guide to the development and clinical testing of vaccines for human use. 1999.
  58. Wessels MR, Paoletti LC, Guttormsen HK, Michon F, D'Ambra AJ, Kasper DL. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun. 1998 May; 66(5):2186-92.
    View in: PubMed
  59. Paoletti LC, Pinel J, Rodewald AK, Kasper DL. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. J Infect Dis. 1997 May; 175(5):1237-9.
    View in: PubMed
  60. Brisson JR, Uhrinova S, Woods RJ, van der Zwan M, Jarrell HC, Paoletti LC, Kasper DL, Jennings HJ. NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry. 1997 Mar 18; 36(11):3278-92.
    View in: PubMed
  61. Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996 Nov 15; 98(10):2308-14.
    View in: PubMed
  62. Kogan G, Uhrín D, Brisson JR, Paoletti LC, Blodgett AE, Kasper DL, Jennings HJ. Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide. J Biol Chem. 1996 Apr 12; 271(15):8786-90.
    View in: PubMed
  63. Paoletti LC, Ross RA, Johnson KD. Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide. Infect Immun. 1996 Apr; 64(4):1220-6.
    View in: PubMed
  64. Paoletti LC, Kennedy RC, Chanh TC, Kasper DL. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons. Infect Immun. 1996 Feb; 64(2):677-9.
    View in: PubMed
  65. Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis. 1996 Jan; 173(1):142-50.
    View in: PubMed
  66. Paoletti LC, Johnson KD. Purification of preparative quantities of group B Streptococcus type III oligosaccharides. J Chromatogr A. 1995 Jun 30; 705(2):363-8.
    View in: PubMed
  67. Wessels MR, Paoletti LC, Pinel J, Kasper DL. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis. 1995 Apr; 171(4):879-84.
    View in: PubMed
  68. Paoletti LC, Wessels MR, Kasper DL. Optimization of group B streptococcal glycoconjugate vaccines. In R.M. Chanock, F. Brown, H.S. Ginsberg, and E. Norrby (eds.) Vaccines 95. Molecular approaches to the control of infectious diseases. 1995; 113-117.
  69. Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1994 Aug; 62(8):3236-43.
    View in: PubMed
  70. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest. 1994 Jul; 94(1):286-92.
    View in: PubMed
  71. Paoletti LC, Wessels MR, Kasper DL. Efficacy in mice of a tetravalent group B Streptococcus polysaccharide-tetanus toxoid conjugate vaccine. In A. Tortolian (ed.) Pathogenic streptococci: present and future. 1994; 347-348..
  72. Kasper DL, Paoletti LC, Madoff LC, Michel JL, Jennings HJ, Wessels MR. Glycoconjugate vaccines for the prevention of group B streptococcal infections. In E. Norrby, F. Brown, R.M. Chanock, and H.S. Ginsberg (eds.). 1994; 113-117.
  73. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Mouse maternal immunization of group B streptococcal type III polysaccharide-beta C protein elicits protective antibody to multiple serotypes. In A. Tortolian (ed.) Pathogenic streptococci: present and future. 1994.
  74. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1993 Nov; 61(11):4760-6.
    View in: PubMed
  75. Hervás JA, González L, Gil J, Paoletti LC, Madoff LC, Benedí VJ. Neonatal group B streptococcal infection in Mallorca, Spain. Clin Infect Dis. 1993 May; 16(5):714-8.
    View in: PubMed
  76. Lee JC, Takeda S, Livolsi PJ, Paoletti LC. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun. 1993 May; 61(5):1853-8.
    View in: PubMed
  77. Paoletti LC, Wessels MR, Michon F, DiFabio J, Jennings HJ, Kasper DL. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1992 Oct; 60(10):4009-14.
    View in: PubMed
  78. Paoletti LC, Kasper DL, Michon F, DiFabio J, Jennings HJ, Tosteson TD, Wessels MR. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992 Jan; 89(1):203-9.
    View in: PubMed
  79. Paoletti LC, Wessels MR, Michon F, Jennings HJ, Kasper DL. Group B Streptococcus type III glycoconjugate vaccines. Trends in Glycoscience and Glycotechnology. 1992; (17):269-278.
  80. Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990 Nov; 86(5):1428-33.
    View in: PubMed
  81. Paoletti LC, Kasper DL, Michon F, DiFabio J, Holme K, Jennings HJ, Wessels MR. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem. 1990 Oct 25; 265(30):18278-83.
    View in: PubMed
  82. Paoletti LC, Blakemore RP. Iron reduction by Aquaspirillum magnetotacticum. Curr Microbiol. 1988; (17:):339-342..
  83. Paoletti LC, Short KA, Blakemore N, Blakemore RP. Freeze-Thawing of Aquaspirillum magnetotacticum Cells Selectively Releases Periplasmic Proteins. Appl Environ Microbiol. 1987 Oct; 53(10):2590-2.
    View in: PubMed
  84. O'Brien W, Paoletti LC, Blakemore RP. . Spectral analysis of cytochromes in Aquaspirillium magnetotacticum. Curr. Microbiol. 1987; (15):121-127.
  85. Paoletti LC, Blakemore RP. Hydroxamate production by Aquaspirillum magnetotacticum. J Bacteriol. 1986 Jul; 167(1):73-6.
    View in: PubMed
  86. Paoletti LC. Iron assimilaton by Aquaspirillum magnetotacticum. 1984.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Paoletti's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (231) concept(s)
_
Co-Authors
See all (16) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_